The impact of indocyanine green (ICG) angiography in multiple diagnostic imaging for the management of exudative age-related macular degeneration (ARMD): a single blind prospective randomised controlled trial of fluorescein angiography vs FA & ICG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN64352175

Enrollment

240

Registered

2005-09-30

Start date

2004-05-24

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases: Age-related macular degeneration (ARMD) Eye Diseases Age-related macular degeneration (ARMD)

Interventions

Interventions are fluorescein angiography compared with fluorescein angiography and indocyanine green angiography. Added 05/09/2008: trial was stopped due to new treataments available.

Eligibility

Inclusion criteria

Inclusion criteria: 240 patients, of whom 24 are estimated to have retinal angiomatous proliferation (RAP).

Exclusion criteria

Exclusion criteria: No specific exclusion criteria

Design outcomes

Primary

Measure	Time frame
Moderate and severe visual loss defined as loss of three lines or 15 letters (doubling of visual angles) and loss of 6 lines or 30 letters respectively, on a log MAR visual acuity chart, at 4,8 and 12 months.	—

Secondary

Measure	Time frame
1. ICG rates modification of fluorescein based diagnosis and management 2. Specificity and sensitivity of ophthalmic signs predictive of ICG findings	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026